Ischemic heart disease (IHD) is the leading cause of mortality in the United States, and more than 200,000 coronary artery bypass surgeries are performed annually in an effort to treat the disease1. Coronary collaterals, anastomoses between branches of the coronary arterial tree, are a natural bypass that can resupply blood to ischemic tissue downstream of a blockage2; however, people exhibit a wide variation in the extent of their native collateral networks3,4. Patients with IHD who have more extensive coronary collateralization have better outcomes during cardiac events, including reduced infarct size and mortality. Hence, coronary collateral growth (CCG) has been a therapeutic target for over a decade5,6,7. It is of particular interest for the growing number of patients with metabolic syndrome8, who exhibit poorer coronary collateralization9. However, until the process and mechanism of CCG are better understood, attempting to induce CCG for the treatment of IHD is unlikely to be fruitful.
Coronary collaterals have been studied in large animal models, and brief, repetitive occlusions of main coronary arteries have been used to induce CCG in pigs10, dogs11, and rats12. A mouse model of CCG, however, would have more advantages in studying the molecular and cellular mechanisms of CCG because of the many genetically modified mouse lines readily available, including lineage tracing, gene-specific or cell-specific transgenic and knockout lines. Interestingly, unlike humans, mice are reported to have no native coronary collaterals13,14, making them an attractive model to study coronary collateral formation. Indeed, a recent report showed that in patients with obstructive artery disease, nearly half (47%) had no collateralization (Rentrop grade 0)3; thus, a mouse model of CCG could be clinically relevant for patients with minimal native collateralization.
We, therefore, developed a mouse model of CCG induced by repetitive ischemia, with an inflatable balloon occluder over the left anterior descending artery (LAD) that uses a pressure-based inflation system automated with a timer. The repetitive ischemia protocol is able to stimulate collateral growth, as shown in a recent publication14. This mouse model of CCG will provide new insight into the process of CCG at cellular and molecular levels and can be used to validate potential targets to promote CCG.